Zinc binding to major human seminal coagulum proteins

In vitro binding of zinc to proteins of the human ejaculate and of the various male accessory gland secretions was evaluated. The proteins were separated by sodium dodecyl sulfate gel electrophoresis and transferred to nitrocellulose filters that were subsequently incubated with 65ZnCl2. High levels of zinc binding were observed to approximately 20 protein bands (14 to 70 kDa) of the coagulated seminal plasma. There was only low binding to proteins of the spermatozoa and virtually no binding to any protein of the epididymal and prostatic fluids. When sperm liquefaction was allowed to occur, 65ZnCl2 binding to high-molecular weight proteins decreased rapidly, and after 15 min only the binding to proteins of molecular weights less than 25 kDa remained. In addition, zinc concentration was determined both in the centrifugate and in the supernatant after centrifugation of the coagulum. Zinc concentrations in the centrifugate and the supernatant were, respectively, 147 +/- 72 micrograms/g and 31 +/- 22 micrograms/g. The whole supernatant contained only 12% +/- 4% of total sperm zinc. Finally, in highly viscous sperm samples the concentration of zinc was not significantly different from that in normally liquefying sperm (167 +/- 87 micrograms/ml compared to 188 +/- 107 micrograms/ml). The main extracellular targets of prostatic zinc in humans are the secreted seminal vesicle proteins. The role of this binding remains unknown, however, because no direct relationship could be established between the concentrations of this metal and the phenomena of coagulation and liquefaction.     

Study of transferrin concentration in the human seminal plasma

Recently, the seminal plasma transferrin concentration has been reported to be a possible clinical marker of the Sertoli cell function. In the present study we measured the seminal plasma transferrin concentration in patients of male infertility by the method of radial immunodiffusion. The results obtained were as follows. 1. The seminal plasma transferrin concentration is significantly correlated to sperm density (p less than 0.001). However, no significant correlations were obtained to sperm motility, serum LH, FSH and testosterone levels. 2. The seminal plasma transferrin concentration in patients of ductal obstruction was 16.2 +/- 4.1 micrograms/ml, which was approximately 20% of pregnancy-proven men (77.5 +/- 49.0 micrograms/ml). This indicates that seminal plasma transferrin originates mainly from the testis. 3. The seminal plasma transferrin concentrations in oligozoospermic men associated with varicocele and in patients of spermatid arrest were low and their values were 22.1 +/- 7.5 micrograms/ml and 13.0 micrograms/ml, respectively. In these patients the involvement of Sertoli cell dysfunction was suggested. 4. Patients of idiopathic oligozoospermia were divided into two subgroups: patients with high seminal plasma transferrin concentrations (128.3 +/- 23.8 micrograms/ml) and those with low seminal plasma transferrin concentrations (29.8 +/- 0.9 micrograms/ml). The serum gonadotropins levels in the former group was at the same level as those of pregnancy-proven men and the levels of the latter group were significantly elevated. These observations suggest that the two groups thus divided belong to different categories of the disease.     

Effect of zinc on decondensation of human spermatozoa nuclei by heparin

Swelling sperm nuclei were assayed, exposing them to the combine action in increasing amounts of seminal plasma 0.1-1.0 ml (124 +/- 21 micrograms of Zn++/ml). An inhibition of almost 30% in the swollen spermatozoa nuclei was observed with 0.1 ml of seminal plasma (12 micrograms of Zn++/ml) reaching to 71% with 74-124 micrograms of Zn++/ml. Inactivated seminal plasma (boiling) induced the same percentage of inhibition (73%) than normal seminal plasma. Dialyzed seminal plasma (31 micrograms of Zn++/ml) produced an inhibition of 88% of swollen spermatozoa nuclei, the same percentage produced with 30-35 micrograms of zinc ions (ZnCl2). Previous release of sperm zinc by preincubation with EDTA 6 mM changed the decondensation kinetics, making sperm nuclei more susceptible to the action of the glycosaminoglycan. No effect was observed in the presence of calcium ions. Therefore, zinc, among its several physiological roles, may act as a nuclear chromatin stabilizer.     

Low serum iron concentration in acute cholecystitis. A discriminator of severity of infection

This study demonstrates that serum iron levels are significantly depressed during acute cholecystitis. Mean admission serum iron concentration for 18 patients who had required emergency cholecystectomy within 48 hours of hospitalization was 40.9 micrograms/100 ml +/- 27.08 (7.32 mumol/l) while for 108 patients who had undergone elective cholecystectomy in the same 18-month period the mean concentration was 90.5 micrograms/100 ml +/- 34.27 (16.2 mumol/l); a mean difference of 49.6 micrograms/100 ml (3.92 mumol/l) (t = 5.8395, P less than 0.00001). Mean serum iron level in seven patients with culture positive acute cholecystitis was 26.4 micrograms/100 ml +/- 10.45 (4.73 mumol/l), significantly different (P less than 0.05) than in 11 patients with culture negative cholecystitis, 50.3 micrograms/100 ml +/- 30.41 (9.00 mumol/l). Admission serum iron level averaged 25.6 micrograms/100 ml (4.58 mumol/l) in three patients with gangrenous gallbladders and was 18 micrograms/100 ml (3.22 mumol/l) in one patient with empyema of the gallbladder. Determination of serum iron level may help distinguish patients with significant infections requiring urgent surgery from patients with biliary colic.     

Human chorionic gonadotropin beta-subunit in human semen

The level of human seminal chorionic gonadotropin beta-subunit (hCG beta) was determined by radioimmunoassay (RIA). The mean hCG beta level in 34 normal men was 3.7 +/- 1.6 ng/ml, which was much higher than that in serum. The mean hCG beta level for 20 patients with mild oligozoospermia (20-39 x 10(6) sperm/ml) was 2.5 +/- 0.8 ng/ml, that for 34 patients with severe oligozoospermia (1-19 x 10(6) sperm/ml) was 1.7 +/- 0.5 ng/ml, and that for 21 azoospermia was 1.5 +/- 0.6 ng/ml. Thus, the decrease of sperm count was correlated with the decrease of hCG beta. In 17 cases to which testicular biopsy was applied together with sperm counting, the seminal hCG beta level was found to positively correlate with the germinal cell index (the ratio germinal cell count/Sertoli cell count) and with the testicular volume. The level of seminal hCG beta was also found to correlate negatively with the levels of seminal LH and FSH and positively with the level of seminal testosterone. These findings suggest that the production of seminal hCG beta is a process of spermatogenesis and closely related to spermatogenesis. The level of hCG beta in serum was too low to detect, and no relation to that in seminal plasma could be investigated. However, in 6 cases with testicular tumor, the hCG beta level in serum was high, whereas that in seminal plasma was rather low probably because of unilateral secretion. Enhanced production of hCG beta by tumor tissues and the destruction of the blood-testis barrier by proliferation of tumor cells seemed to be one of the causes of this high hCG beta level in serum. The hCG beta levels in 13 vasectomized seminal plasma and the prostatic fluid samples collected from 3 normal men were 1.5 ng/ml, which was similar to those in azoospermic patients. These findings suggest that the seminal hCG beta level consists of the hCG beta secreted by the testis and about 1.5 ng/ml of hCG beta from the prostate. Based on these results, seminal hCG beta is thought to be secreted by the prostate and the process of spermatogenesis and the value of seminal hCG beta may serve as an effective index for the testicular function.     

Clinical observations of plasma fibronectin in patients with urological malignant disease

Fibronectin (FN) is a high molecular weight glycoprotein widely distributed in the body and has a number of biological activities. Recently, there have been reports on the relationship between plasma fibronectin (pFN) levels and malignant diseases, but the significance of pFN is still unclear. Using immunoturbidimetric assay, we measured pFN levels of 24 healthy controls and 61 patients with urological malignant diseases, and obtained the following results. 1. pFN levels before treatment. 1) pFN level was 379 +/- 60.6 micrograms/ml and 356 +/- 123.7 micrograms/ml in the healthy controls and patients, respectively. There was no significant difference. 2) pFN level in patients with metastases was 320 +/- 92.9 micrograms/ml and had no statistical difference as compared with patients without metastases (371 +/- 132.7 micrograms/ml) and controls, despite the decrease in the mean value. 3) pFN level in patients with poor prognosis (300 +/- 107.8 micrograms/ml) was significantly lower than that in patients with good prognosis (410 +/- 157.2 micrograms/ml) and controls (p less than 0.05). 2. pFN levels during conservative treatments for advanced disease. pFN level in patients with a rapid progressive disease (287 +/- 64.4 micrograms/ml) was significantly lower than that in patients with a slow progressive disease (327 +/- 43.3 micrograms/ml) (p less than 0.01). These data suggest that low pFN level predicts rapid progression of the disease and poor prognosis in patients with a urological malignant disease.     

Copper concentration in seminal plasma of infertile men: influence of hormone therapy on copper concentration in seminal plasma

The copper concentration in semen was measured in 30 subjects with male sterility and in 7 normal males and the relationship with the concentration of sperms was investigated. Copper concentration in semen was also measured before and after hormone therapy in the other 10 cases. The mean and standard deviation of seminal copper concentration in the normal males were 89.71 +/- 80.84 micrograms/dl. The mean and standard deviations by sperm frequency were 39.75 +/- 29.35 micrograms/dl for less than 45 x 10(6) sperms/ml, 31.93 +/- 38.20 micrograms/dl for less than 15 x 10(6) sperms/ml and 19.54 +/- 10.89 micrograms/dl for azoospermia. A significant decrease in seminal copper concentration was found with decrease in the concentration of sperms. The copper concentration in the hormone-treated group increased 3-32 times or 11 times on the average after treatment compared with the pre-treatment values. In the ten subjects, the mean and standard deviations were 18.30 +/- 10.49 micrograms/dl before treatment and 159.80 +/- 148.81 micrograms/dl after treatment representing a significant post-treatment increase in seminal copper concentration.     

Josamycin Concentration in Human Ejaculate and its Influence on Sperm Motility/Josamycinkonzentrationsbestimmung in menschlichem Ejakulat und deren Einfluß auf die Spermienmotilität

The concentration of josamycin was determined in the split ejaculate of 5 volunteers after oral administration for several days. One aim of this investigation was to examine the penetration of the macrolide antibiotic into the prostate and the seminal vesicles. 2.23 +/- 1.8 micrograms/ml josamycin was found in fraction I of the ejaculate, consisting mostly of prostatic secretion, and 1.56 +/- 1.37 micrograms/ml josamycin in fraction II comprising mainly secretions from the seminal vesicles. The concentrations of josamycin found in both fractions of the ejaculate are clearly comparable with serum levels of the antibiotic. Josamycin thus attains concentrations in the prostate and seminal vesicles which are effective against Mycoplasma and Chlamydia, pathogens of increasing importance in infections of the urogenital tract. In vitro studies on samples from 30 andrological patients showed that josamycin (0.5 micrograms/ml) did not impair, but even increased the motility of spermatozoa (p less than or equal to 0.01). On the basis of these results josamycin is recommended for the treatment of andrological patients. In particular, the specific antibacterial spectrum also indicates the use of this antibiotic for treatment of the partner when children are desired. The usual precautionary measures for pregnancy must then be adhered to.     

Epoxycholesterols in secretions and tissues of normal, benign, and cancerous human prostate glands

Extracts of prostatic secretions taken from 25 control subjects, twenty-three to seventy-five years of age, were analyzed by gas-liquid chromatography (GLC) for cholesterol and possible epoxycholesterol content. Only subjects fifty-three years or older exhibited any signs of prostatic enlargement. Whereas cholesterol (893 +/- 133 micrograms/ml) was found in all prostatic secretions, the carcinogenic epoxycholesterols (22.6 +/- 3.3 micrograms/ml) were detected only in one third of the specimens examined. Prostatic secretion collected from 29 surgical patients prior to primary (20) and secondary (9) prostatectomies revealed cholesterol contents of 1,182 +/- 148 and 1,134 +/- 157 micrograms/ml, respectively. The epoxycholesterols were essentially present at concentrations of 33.7 +/- 7.9 and 24.0 +/- 10.3 micrograms/ml, respectively. Tissue extracts of the different prostatic lobes taken from 40 surgical BPH patients at the time of primary (26) and secondary (14) prostatectomy were examined by capillary GLC. Of these patients 8 had prostatic carcinoma. The cholesterol content of all tissues was essentially double that of normal prostates. The epoxycholesterols were present in all tissues. The mean cholesterol 5 alpha, 6 alpha-epoxide and cholesterol 5 beta, 6 beta-epoxide contents of all tissue were 120 +/- 23.4 and 9.9 +/- 5.2 micrograms/Gm dry tissue, respectively. There were no apparent differences beteeen the lobes nor between BPH and cancers. No epoxycholesterol could be detected in 8 seminal vesicles obtained at autopsy.     

Magnesium and zinc in seminal fluid of healthy males and patients with non-acute prostatitis with and without gonorrhoea.

The concentrations of magnesium and zinc in the seminal fluid of 41 patients with symptoms of non-acute prostatitis and of 11 healthy age-matched males were determined by atomic absorption spectrophotometry. Possible sources of error in the determination of these metals in seminal fluid are discussed. The mean concentration of magnesium in the patients was 56.6 mug/ml (range 19-190) and in the controls 64.5 mug/ml (range 36-165). The corresponding figures for zinc were 79.2 mug/ml (range 13-283) and 67.5 mug/mg (range 34-116). Both in the patients and in the controls there was a significant correlation between the concentration of magnesium and that of zinc. No significant difference was found between the patients and the controls regarding the concentration of magnesium or zinc. From none of the patients could gonococci be cultured. However, in 6 of them, immunofluorescent studies revealed gonococci. The concentration of zinc (48.3 mug/ml) in seminal fluid from these 6 patients was significantly lower than in the remaining 35. Neither in the patients, nor in the controls, was any correlation found between the concentration of magnesium or zinc and that of fructose in seminal fluid. A significant correlation was found between the concentrations of these metals and the antibacterial activity (determined as the inhibitory effect on the growth of Staphylococcus albus) of the seminal fluid from the patients. A negative correlation was found between the concentration of zinc and an increase in the number of white blood cells in expressed prostatic fluid. No correlation was found between magnesium or zinc and the number of spermatozoa or the percentage of abnormal spermatozoa. The findings in the present study suggest that the secretion of magnesium and zinc is decreased in prostatitis. Because of the wide range of variation of magnesium and zinc in seminal fluid of healthy males, determination of these metals is of limited value in the diagnoses of prostatitis in a given case.     

Seminal plasma transferrin concentration in idiopathic oligozoospermia

To investigate whether or not transferrin production is decreased in the testis of idiopathic oligozoospermia, the seminal plasma transferrin concentration was measured and the values were compared in two groups (15 men of pregnancy-proved normozoospermia and 22 patients with idiopathic oligozoospermia). Seminal plasma transferrin concentration in the pregnancy-proved normozoospermic group was 78.5 +/- 37.9 micrograms/mL, and the concentration in the patients with idiopathic oligozoospermia was 44.4 +/- 37.6 micrograms/mL. There was a significant difference between them (P less than 0.01). The patients with idiopathic oligozoospermia could be divided into two subgroups according to seminal plasma transferrin concentration and serum gonadotropin levels. One group had high transferrin levels with elevated serum gonadotropin levels. The results indicate that the determination of seminal plasma transferrin concentration is one of the useful parameters for evaluation of testicular function and also suggest that additional studies may allow for the subdivision of the patients with so-called idiopathic oligozoospermia.     

Human Seminal Plasma Cadmium: Comparison with Fertility and Smoking Habits/Cadmium in menschlichem Seminalplasma: Vergleich zwischen Fertilität und Rauchgewohnheiten

Cadmium, selenium and zinc were determined in seminal plasma and serum of 64 men by atomic absorption spectrometry (AAS). The mean (+/- SD) cadmium concentrations in seminal plasma and serum were 0.22 +/- 0.22 micrograms and 0.28 +/- 0.10 micrograms, respectively, but they did not correlate with each other. Smokers (n = 31) had significantly (p less than 0.01) higher serum cadmium concentrations than non-smokers (n = 31). Also seminal plasma cadmium in smokers was elevated, but a significant difference to non-smokers was only found if more than 20 cigarettes were consumed daily. No differences were found in semen quality and fertility between smokers and non-smokers. The seminal plasma cadmium had no correlation to selenium or zinc which, however, displayed a positive correlation (r = 0.852, p less than 0.001) to each other. It is concluded that smoking increases the exposure to cadmium. Although no obvious reproductive suppression was observed, heavy smoking may possibly enhance toxic effects in men under other detrimental exposures.     

Serum zinc and copper levels in healthy middle and higher socio-economic class infants in Cape Town. A longitudinal study during the 1st year of life

Serum zinc and copper levels were measured using a flame atomic absorption technique in 55 healthy infants and their middle and upper socio-economic class mothers at delivery, and also longitudinally in the infants during the first 12 months of life. Mean cord serum zinc levels (99.50 +/- 27.63 micrograms/100 ml) were 1.5 times higher than maternal serum levels at birth (66.3 +/- 21.0 micrograms/100 ml). The mean serum zinc levels showed no significant change (P greater than 0.05) at each of the study periods. However, the mean serum zinc levels at birth were significantly higher (P less than 0.05), than those after 6 weeks. The infants' levels remained within the normal adult range at all the study periods. The mean cord serum copper levels (34.46 +/- 12.60 micrograms/100 ml) were about one-sixth of the mean maternal serum copper levels at delivery (217.7 +/- 64.39 micrograms/100 ml). The mean serum copper levels increased significantly (P less than 0.05) from birth to 12 months of age. Mean serum copper levels similar to those of normal adults were reached at 12-24 weeks.     

Vasectomy and vasovasostomy have no effect on seminal plasma zinc concentrations

Mean zinc concentrations were determined for human seminal plasma obtained from 110 nonvasectomized men (139 micrograms. per ml.), 43 recently vasectomized men (144 micrograms. per ml.), 25 long-term vasectomized men (139 micrograms. per ml.) and 25 men who had undergone vasovasostomy (129 micrograms. per ml.). The results indicate that there is no significant short-term or long-term effect of these surgical procedures on prostatic secretory function as measured by seminal plasma zinc concentration.     

Seminal plasma prostate-specific antigen level in benign prostatic hyperplasia

INTRODUCTION: We evaluated the role of the seminal plasma PSA level in the prediction of the response to alpha-blocker treatment in patients with benign prostatic hyperplasia. MATERIALS AND METHODS: 18 male patients with lower urinary tract symptoms were enrolled in the study. After their blood was sampled for PSA, ejaculates of all the subjects were obtained. Serum and seminal plasma PSA levels were calculated by Active PSA IRMA kit. Patients were given 4 mg/day doxazosin for a period of 6 weeks, following which their International Prostate Symptom Score (IPSS) evaluation was repeated. The correlation between serum PSA, seminal plasma PSA and PSA density levels and the percentage improvement in IPSS was investigated. RESULTS: The mean serum PSA level, the mean PSA density and the mean seminal PSA level of the patients were 2.7 +/- 1.2 ng/ml, 0.05 +/- 0.02 ng/ml/cm(3) and 0.7 +/- 0.39 g/l, respectively. The percentage improvement in IPSS varied from 26.9 to 53.5%. Serum PSA and serum PSA density were not useful in the prediction of the response to alpha-blocker treatment, but the seminal PSA levels correlated with the percentage improvement in the IPSS (p = 0.017). CONCLUSIONS: Seminal plasma PSA has been found to be a better predictor of the response to alpha-blocker treatment when compared to serum PSA and PSA density.     

Comparative study of zinc levels in benign and malignant lesions of the prostate

OBJECTIVES: The normal human prostate accumulates the highest levels of zinc of any soft tissue in the body. The presence of zinc in the prostate of a number of mammalian species, including rhesus monkeys and humans, has been well documented. The aims of this study were to investigate the concentrations of zinc in various disorders of the prostate and to find a correlation between them. MATERIAL AND METHODS: A total of 80 cases were studied (20 normal, 50 benign, 10 carcinomatous). A plasma sample was taken and zinc levels were analyzed using atomic absorption spectrophotometry. RESULTS: The mean (+/-SD) plasma zinc level in the normal cases was 94.5+/-10.38 microg/100 ml. Amongst patients with benign diseases of the prostate gland, the plasma zinc level was 145.4+/-9.67, 162.4+/-2.22 and 172.7+/-5.27 microg/100 ml (78% rise compared to normal patients) in those with a fibromuscular prostate, chronic prostatitis and benign prostatic hyperplasia, respectively, whilst patients with malignancy had a plasma zinc level of 59.6+/-3.08 microg/100 ml (37% fall compared to normal patients). There was a highly statistically significant (p < 0.01) difference in plasma zinc levels between patients with benign and malignant prostate diseases. The effect of metastasis of carcinoma of the prostate on plasma zinc levels was not significant (p > 0.05), while there was a highly statistically significant (p < 0.01) correlation between serum prostate-specific antigen and plasma zinc levels in malignancy. CONCLUSIONS: There appears to be a strong correlation between plasma zinc levels and various prostatic diseases. Therefore, the determination of zinc levels can be used as a diagnostic or screening tool and may lead to the formulation of methods in which zinc is used to evaluate prostatic pathology.     

Renal kallikrein and hemodynamic abnormalities of diabetic kidney.

The relationship between renal hemodynamic abnormalities and renal kallikrein activity was studied in streptozocin-induced diabetic rats. Diabetic rats were either not treated with insulin and had plasma glucose levels greater than 400 mg/dl (severely hyperglycemic diabetic [SD]) or were treated with 1.5-1.75 U/day protamine zinc insulin and had glucose levels of 200-300 mg/dl (moderately hyperglycemic diabetic [MD]). In SD rats, kidney tissue level and excretion of active kallikrein were reduced after 3 wk compared with age-matched nondiabetic control rats (tissue, 11.7 +/- 1.9 vs. 20.5 +/- 1.8 ng/mg protein, P less than 0.005; urine, 126 +/- 12 vs. 179 +/- 10 micrograms/24 h, P less than 0.005). Despite increased kidney size, renal plasma flow (RPF) was reduced in SD rats (5.38 +/- 0.23 vs. 6.37 +/- 0.20 ml/min, P less than 0.05). Glomerular filtration rate (GFR) was not significantly lower (2.77 +/- 0.60 vs. 3.02 +/- 0.56 ml/min). In MD rats, kidney tissue level and excretion of active kallikrein were increased after 5 wk compared with age-matched nondiabetic control rats (tissue, 28.4 +/- 1.3 vs. 23.3 +/- 1.7 ng/mg protein, P less than 0.05; urine, 289 +/- 16 vs. 196 +/- 13 micrograms/24 h, P less than 0.001). In MD rats, GFR and RPF were increased (3.80 +/- 0.11 and 8.04 +/- 0.17 ml/min, respectively) compared with control rats (3.22 +/- 0.05 and 7.28 +/- 0.09 ml/min, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)     

Evaluation of the effect of experimental cyclosporine toxicity on male reproduction and renal function. Reversal by concomitant human chorionic gonadotropin administration

Administration of cyclosporine to rats has been shown to impair testicular function, resulting in a decrease in sperm counts and fertility. In order to determine whether or not the deleterious effects of CsA could be reversed by hormonal therapy, mature male Sprague Dawley rats were treated with CsA (40 mg/kg/day, s.c.) alone or in combination with human chorionic gonadotropin (hCG) (5 micrograms/day/r; s.c.) for 14 days. Cyclosporine administration decreased the body weight (290 +/- 5.30 vs. 339 +/- 8.7 g; P less than 0.05) and reproductive organ weights (testis 1.49 +/- 0.42 vs. 1.60 +/- 0.03 g; epididymis 0.41 +/- 0.02 vs. 0.49 +/- 0.002 g; seminal vesicle 0.61 +/- 0.09 vs. 1.60 +/- 0.05 g; prostate 0.28 +/- 0.04 vs. 0.60 +/- 0.06 g; P less than 0.05) testicular sperm counts (5.80 +/- 0.42 vs. 8.49 +/- 0.48 x 10(7)/100 mg tissue; P less than 0.05) and epididymal sperm counts, (28.2 +/- 0.95 vs. 51 51.62 +/- 2.17 x 10(7)/100 mg tissue; P less than 0.05) and fertility (25% vs. 100%). Serum levels of LH were elevated (101.98 +/- 21.48 vs. 25.6 +/- 5.18 ng/ml; P less than 0.05) and testosterone was decreased (0.48 +/- 0.07 vs. 2.06 +/- 0.56 ng/ml; P less than 0.05). The administration of hCG to the CsA-treated rats restored the reproductive organ weights (testis 1.56 +/- 0.043 g; seminal vesicle 1.04 +/- 0.05 g; prostate 0.70 +/- 0.06 g) and sperm counts (testicular 7.88 +/- 1.0 x 10(7)/100 mg tissue; epididymal 59.86 +/- 4.16 x 10(7)/100 mg tissue; P less than 0.05) Serum levels of testosterone (18.63 +/- 4.45 ng/ml) and LH (431.65 +/- 31.41 ng/ml) were significantly elevated, as compared with control and CsA-treated groups (P less than 0.05). All the rats in the gonadotropin-treated group were fertile, as compared with 25% in the CsA-treated group. CsA reduced the kidney weight (1.17 +/- 0.02 vs. 1.27 +/- 0.03 g; P less than 0.05) and increased the levels of serum creatinine (0.97 +/- 0.07 vs. 0.59 +/- 0.03 mg/dl; P less than 0.05): these changes were ameliorated by the administration of hCG (kidney weight 1.35 +/- 0.03 g; creatinine 0.76 +/- 0.09 mg/dl).     

Alpha-glucosidase in the human epididymis: topographic distribution and clinical application

Alpha-glucosidase activity (EC.3.2.1.20) is present in human seminal plasma, and the neutral form of the enzyme originates almost exclusively from the epididymis. In this study, the specific immunocytochemical location of alpha-glucosidase in the human epididymis was evaluated using a polyclonal antibody. Furthermore, a spectrophotometric assay was employed to assess epididymal obstruction in infertile patients. The enzymatic activity of alpha-glucosidase free of prostate isoform (AGFPI) was determined spectrophotometrically at 405 nm. According to AGFPI activity, patients with leucocytospermia, oligozoospermia and azoospermia were recorded as having normal values or low values indicating epididymal obstruction. Specific immunochemistry staining was demonstrated in the cytoplasmic cells at the epithelial level, in the transition area and in the efferent ducts. The values of the three groups and the control were as follows (mean +/- SEM): normozoospermia (control): 20.2 +/- 1.4 mU ml(-1); azoospermia: normal value: 17.6 +/- 2.2 mU ml(-1), low value: 7.4 +/- 1.8 mU ml(-1); oligozoospermia: normal value: 22.3 +/- 2.5 mU ml(-1), low value: 7.3 +/- 0.7 mU ml(-1); leucocytospermia: increase value: 38.9 +/- 3.7 mU ml(-1), low value: 11.1 +/-1.3 mU ml(-1). This study suggests that determination of alpha-glucosidase might be helpful to evaluate functions of the epididymis and particularly to exclude epididymal obstruction.     

Whole blood serotonin levels are markedly elevated in patients on dialytic therapy.

The normal range for whole blood serotonin levels in chronic renal failure patients has not been defined. As serotonin may be implicated in platelet abnormalities, hypo- and hypertension and itch in dialysis patients, serotonin whole blood levels were measured in a group of patients with chronic renal failure and/or who were dialysis dependent. The levels were elevated in 12 patients with moderate (mean serum creatinine 335 +/- 54 mumol/l) chronic renal failure (270 +/- 46 micrograms/l) compared to 11 normals (163 +/- 17 micrograms/l, p less than 0.05; quoted normal range less than 300 micrograms/l) but did not correlate with serum creatinine levels. There was a marked elevation in serotonin levels in dialyzed patients, including those on hemodialysis (polysulfone, n = 6, 747 +/- 234 micrograms/l; cuprophane membranes, n = 6, 708 +/- 198 micrograms/l), hemodiafiltration (n = 12, 695 +/- 130 micrograms/l) and especially peritoneal dialysis (n = 6, 1,148 +/- 162 micrograms/l). All results were significant (p less than 0.01) compared to normals and compared to the nondialyzed group (p less than 0.05). The level of serotonin decreased during hemodialysis regardless of the membrane used. There was no positive correlation of serotonin levels with pruritus or hypertension, although there was a negative correlation with systolic blood pressure. The reference range for serotonin whole blood levels needs to be broadened when considering dialyzed patients.